Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Novo Nordisk (NVO 0.76%), a Danish pharmaceutical company, is the developer of Ozempic, which is often referred to as a weight-loss drug.But there is actually a nuance, albeit an important one, to ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

It could take years before Novo Nordisk has fulfilled demand for weight loss drugs, the company’s chief executive told CNN, noting there are more than 100 million Americans with obesity and that ...

Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.

Ozempic’s net price has gone down by 40% since it was introduced in the U.S., Novo Nordisk said last week. Wegovy, too, is “following a similar trajectory.” ...

Novo Nordisk has made nearly $50 billion on the sales of Ozempic and Wegovy since 2018, Sanders said. He described the U.S. as a "cash cow" for Novo Nordisk, accounting for 72% of the company's ...

LONDON, May 2 (Reuters) – Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have ...